Fig. 1: SLAMF6 is expressed on AML stem cells.

a, Schematic overview of the antibody screen to identify novel markers differentially expressed on CD34⁺CD38^low cells from NBM and from participants with AML with TP53 mutations by flow cytometry. b, Most highly expressed cell surface markers on CD34⁺CD38^low cells in AML (n = 3 participants) compared to NBM (n = 3 donors) samples. Previously identified AML markers are shown in bold. c, Expression of SLAMF6 on CD34⁺CD38^low cells from representative samples from NBM and a participant with AML. d, SLAMF6 expression on the three AML cases and three NBM samples included in the antibody screen (two-sided t-test, P = 0.011). e, Expression of SLAMF6 on normal hematopoietic cell populations in peripheral blood from healthy donors (one representative donor of four). f, Expression of SLAMF6 in hematopoietic cell types based on scRNA-seq of mononuclear cells from five NBM donors and CD34⁺ cells from three donors. In the violin plot, dots represent individual donors, bars indicate median values and blue shading indicates density. g, SLAMF6 expression in NBM populations from an scRNA-seq dataset with ten healthy donors²⁹. In the violin plot, dots represent individual donors, bars indicate median values and blue shading indicates density.

Source Data